Marc Beer announces new products in the works by Renovia

Marc Beer announces new products in the works by Renovia

Renovia Inc. has recently announced that they are moving forward with several new products to diagnose and treat pelvic floor disorders. This includes a new generation of their Leva device, which was their first product to receive FDA approval. A total of four products are currently planned, for which $42 million dollars were raised.

 

Pelvic floor disorders are estimated to affect as many as 250 million women worldwide. To help these women, a healthcare-focused investing firm known as The Longwood Fund has joined Renovia in their current phase of development. The Longwood Fund was an early investor in Renovia.

 

Renovia’s co-founder, Marc Beer, is quoted as saying, “We are thrilled to have the support of this group of leading healthcare investors who share our vision to better diagnose, treat and improve the lives of millions of women affected by pelvic floor disorders. Combining our innovative and proprietary sensor technologies and form factors with a digital health platform will give our customers valuable data to inform new treatment options, drive greater knowledge and understanding of pelvic floor disorders, and ultimately lower long-term healthcare costs.”

 

This is not the first time that Marc Beer has set his sights on improving the treatments and options available to women. Marc became the Founding CEO of ViaCell In April 2000, a company which specialized in collecting and preserving stem cells found in umbilical cord blood, which many new mothers choose to bank in the hope that the cells can be used to help their children in the future, should they become sick.

 

Marc has also focused his attention on those suffering from rare and debilitating illnesses. He was formerly Chief Executive Officer of a pharmaceutical company. which developed the product JUXTAPID® (lomitapide) for the treatment of homozygous familial hypercholesterolemia. Their second product, MYALEPT® (metreleptin), is used for the treatment of generalized lipodystrophy.

 

During his time at ViaCell, Marc also sat on the board of directors of Erytech Pharma, as well as filling various roles at Genzyme, including as Vice President of Global Marketing. Marc graduated from Miami University with a Bachelor’s of Science, which he has no doubt put to good use. Learn more : https://www.slideshare.net/MarcBeer

Leave a Reply

Your email address will not be published. Required fields are marked *